169 related articles for article (PubMed ID: 12707316)
1. Cutting edge: CD8+ effector T cells reject tumors by direct antigen recognition but indirect action on host cells.
Schüler T; Blankenstein T
J Immunol; 2003 May; 170(9):4427-31. PubMed ID: 12707316
[TBL] [Abstract][Full Text] [Related]
2. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
[TBL] [Abstract][Full Text] [Related]
3. Tc1 and Tc2 effector cell therapy elicit long-term tumor immunity by contrasting mechanisms that result in complementary endogenous type 1 antitumor responses.
Dobrzanski MJ; Reome JB; Hollenbaugh JA; Dutton RW
J Immunol; 2004 Feb; 172(3):1380-90. PubMed ID: 14734713
[TBL] [Abstract][Full Text] [Related]
4. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
5. Role of CD4+ and CD8+ T cells in allorecognition: lessons from corneal transplantation.
Boisgérault F; Liu Y; Anosova N; Ehrlich E; Dana MR; Benichou G
J Immunol; 2001 Aug; 167(4):1891-9. PubMed ID: 11489968
[TBL] [Abstract][Full Text] [Related]
6. Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors.
Plautz GE; Mukai S; Cohen PA; Shu S
J Immunol; 2000 Oct; 165(7):3656-62. PubMed ID: 11034369
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of antigen presentation to T cells in murine graft-versus-host disease: cross-presentation and the appearance of cross-presentation.
Wang X; Li H; Matte-Martone C; Cui W; Li N; Tan HS; Roopenian D; Shlomchik WD
Blood; 2011 Dec; 118(24):6426-37. PubMed ID: 21963602
[TBL] [Abstract][Full Text] [Related]
8. Type 1 and type 2 CD8+ effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor.
Dobrzanski MJ; Reome JB; Dutton RW
J Immunol; 2000 Jan; 164(2):916-25. PubMed ID: 10623840
[TBL] [Abstract][Full Text] [Related]
9. CD4
Haabeth OAW; Fauskanger M; Manzke M; Lundin KU; Corthay A; Bogen B; Tveita AA
Cancer Res; 2018 Aug; 78(16):4573-4585. PubMed ID: 29752262
[TBL] [Abstract][Full Text] [Related]
10. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas.
Böhm W; Thoma S; Leithäuser F; Möller P; Schirmbeck R; Reimann J
J Immunol; 1998 Jul; 161(2):897-908. PubMed ID: 9670968
[TBL] [Abstract][Full Text] [Related]
11. A bone marrow-derived APC in the gut-associated lymphoid tissue captures oral antigens and presents them to both CD4+ and CD8+ T cells.
Blanas E; Davey GM; Carbone FR; Heath WR
J Immunol; 2000 Mar; 164(6):2890-6. PubMed ID: 10706674
[TBL] [Abstract][Full Text] [Related]
12. Incomplete differentiation of antigen-specific CD8 T cells in tumor-draining lymph nodes.
Hargadon KM; Brinkman CC; Sheasley-O'neill SL; Nichols LA; Bullock TN; Engelhard VH
J Immunol; 2006 Nov; 177(9):6081-90. PubMed ID: 17056534
[TBL] [Abstract][Full Text] [Related]
13. IFN-gamma receptor signaling regulates memory CD8+ T cell differentiation.
Sercan O; Stoycheva D; Hämmerling GJ; Arnold B; Schüler T
J Immunol; 2010 Mar; 184(6):2855-62. PubMed ID: 20164422
[TBL] [Abstract][Full Text] [Related]
14. Efficient in vivo presentation of Listeria monocytogenes- derived CD4 and CD8 T cell epitopes in the absence of IFN-gamma.
Skoberne M; Geginat G
J Immunol; 2002 Feb; 168(4):1854-60. PubMed ID: 11823519
[TBL] [Abstract][Full Text] [Related]
15. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection.
Dobrzanski MJ; Reome JB; Dutton RW
Clin Immunol; 2001 Jan; 98(1):70-84. PubMed ID: 11141329
[TBL] [Abstract][Full Text] [Related]
16. An essential contribution by IFN-gamma to CD8+ T cell-mediated rejection of pancreatic islet allografts.
Diamond AS; Gill RG
J Immunol; 2000 Jul; 165(1):247-55. PubMed ID: 10861058
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.
Bates JT; Graff AH; Phipps JP; Grayson JM; Mizel SB
J Immunol; 2011 Jun; 186(11):6255-62. PubMed ID: 21515787
[TBL] [Abstract][Full Text] [Related]
18. Innate immune cells contribute to the IFN-gamma-dependent regulation of antigen-specific CD8+ T cell homeostasis.
Sercan O; Hämmerling GJ; Arnold B; Schüler T
J Immunol; 2006 Jan; 176(2):735-9. PubMed ID: 16393956
[TBL] [Abstract][Full Text] [Related]
19. IFN-γ-producing effector CD8 T lymphocytes cause immune glomerular injury by recognizing antigen presented as immune complex on target tissue.
Tsumiyama K; Hashiramoto A; Takimoto M; Tsuji-Kawahara S; Miyazawa M; Shiozawa S
J Immunol; 2013 Jul; 191(1):91-6. PubMed ID: 23720810
[TBL] [Abstract][Full Text] [Related]
20. Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.
Thompson ED; Enriquez HL; Fu YX; Engelhard VH
J Exp Med; 2010 Aug; 207(8):1791-804. PubMed ID: 20660615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
